SCHEMBL26686403

SCHEMBL26686403

Nc1n[nH]c2ccc(-c3ccnc(NC4CCCCC4)c3)cc12

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 5/20 0.52
▸ PDPK1 O15530 2/20 0.52
▸ AURKA O14965 1/20 0.52
▸ TGFBR1 P36897 1/20 0.52
▸ ROCK1 Q13464 1/20 0.52
▸ AURKB Q96GD4 1/20 0.52
▸ CDC7 O00311 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ DYRK1A Q13627 3/20 0.45
▸ WNT1 P04628 1/20 0.45
▸ MAPK14 Q16539 4/20 0.45
▸ MAPK9 P45984 2/20 0.45
▸ MAPK10 P53779 2/20 0.45
▸ MAPK8 P45983 1/20 0.45
▸ PRKD1 Q15139 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26686081 0.88 MAPK14 (0.53) JAK2PDPK1AURKATGFBR1ROCK1
SCHEMBL31240888 0.88 JAK2 (0.50) JAK2PDPK1AURKATGFBR1ROCK1
SCHEMBL30633334 0.88 MAPK14 (0.53) JAK2PDPK1AURKATGFBR1ROCK1
SCHEMBL26685977 0.88 JAK2 (0.50) JAK2PDPK1AURKATGFBR1ROCK1
SCHEMBL26686055 0.84 DYRK1A (0.52) DYRK1AWNT1
SCHEMBL30633289 0.84 DYRK1A (0.52) DYRK1AWNT1
SCHEMBL26685950 0.82 DYRK1A (0.51) JAK2DYRK1AWNT1
SCHEMBL31420125 0.82 DYRK1A (0.51) JAK2DYRK1AWNT1
SCHEMBL26686529 0.81 CDC7 (0.45) PDPK1AURKATGFBR1ROCK1AURKB
SCHEMBL31240358 0.79 ULK1 (0.61) JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP claimed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US claimed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP claimed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN claimed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO claimed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO claimed
EP-4705291-A1 IKK-ALPHA INHIBITORS Cancer Research Technology Limited (GB) 2026-03-11 — — EP disclosed
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN disclosed
WO-2024228035-A1 IKK-ALPHA INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-11-07 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB JAK2 207/4885PDPK1 522/4885AURKA 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback